

Please type a plus sign (+) inside this box →

RECEIVED
FEB 12 2003
AP 1600

TECH CENTER 1000/2000
PTO/SB/21 (08-00)

Approved for use through 10/31/2002 GPO: 2002-0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	09/509,196
		Filing Date	March 23, 2000
		First Named Inventor	DALY, ROGER JOHN
		Group Art Unit	1646
		Examiner Name	CHERNYSHEV, OLGA N.
Total Number of Pages in This Submission	33	Attorney Docket Number	RICE-012

ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input checked="" type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input checked="" type="checkbox"/> Declaration of Yasumichi Hitoshi	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
1) Exhibit 1 Curriculum Vitae of Yasumichi Hitoshi	<input type="checkbox"/> Power of Attorney, Revocation	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Postcard
2) Exhibit 2: Primers used in expression analysis of 2.2412	<input type="checkbox"/> Change of Correspondence Address	
2) Graphs showing expression of 2.2412 in normal and cancerous human cells	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name	CAROL L. FRANCIS, Reg. No. 36,513
Signature	
Date	February 4, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: February 4, 2003.

Typed or printed name	Steven E. Goldstein	Date	February 4, 2003
Signature			

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: February 4, 2003.

Typed or Printed Name	Steven F. Goldstein	Date	February 4, 2003
Signature			

AMENDMENT UNDER 37 C.F.R. §1.116		Attorney Docket Confirmation No.	RICE-012 8868
Address to: Box AF Assistant Commissioner for Patents Washington, D.C. 20231		First Named Inventor	Roger John Daly
		Application Number	09/509,196
		Filing Date	March 23, 2000
		Group Art Unit	1646
		Examiner Name	Olga N. Chernyshev
		Title	"Potential Effector for the GRB7 Family of Signalling Proteins"

Sir:

This amendment is responsive to the Final Office Action dated November 5, 2002 for which a three-month period for response was given making this response due on or before February 5, 2003. In view of the amendments to the claims and the remarks put forth below, reconsideration and allowance are respectfully requested. Applicants have attached to this amendment a "Version with Markings to Show Changes Made" wherein all of the amendments requested here are put forth with underlining and bracketing.

Applicants submit that the amendments set forth below raise no new issues. Rather, the amendments place the claims in form for allowance or in better form for appeal. Entry of these amendments is thus respectfully requested.

AMENDMENTS

IN THE CLAIMS

Please replace the pending claims with their correspondingly numbered claims below.

Claims 23 and 30 are canceled without prejudice.

Claims 1 and 22 are amended.

- E1*
- 1. (Thrice Amended)** An isolated polynucleotide molecule encoding an effector protein for the Grb7 family of signalling proteins, wherein the polynucleotide molecule comprises a nucleotide sequence encoding an amino acid sequence having at least 95% sequence identity to the amino acid sequence as shown in SEQ ID NO:2.